ArticleScientific reports2025
A DFT investigation of the adsorption mechanism of paclitaxel on functionalized graphene oxide for enhanced drug delivery.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Synthesis, Characterization and Molecular Modeling of Novel Oxoethyl methacrylate Polymers.ACS omega · 2025Article
- Theoretical investigation of penicillamine adsorption on mgScientific reports · 2025Article
- Cheminformatics-based screening and evaluation of phytochemicals as CDK2 inhibitors in colorectal cancer therapy.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of effective drug delivery systems is vital for enhancing the therapeutic efficacy of anticancer agents, particularly paclitaxel (PTX). Despite its potent anticancer properties, PTX faces limitations due to poor solubility and non-specific distribution, leading to significant side effects. To address these challenges, researchers have explored the use of reduced graphene oxide (rGO) as a nanocarrier. Functionalized rGO exhibits unique physicochemical properties, including high surface area and biocompatibility, which enhance drug loading capacity. This study investigates the adsorption mechanisms of PTX on various functionalized rGO surfaces, utilizing computational methods such as Density Functional Theory and Molecular Dynamics simulations. The results demonstrate that functionalization with hydroxyl (-OH), carboxyl (-COOH), and sulfonic (-SO) groups significantly influences the adsorption energy and charge transfer characteristics of PTX on GO. The adsorption energies calculated for PTX@rGO-OH and PTX@rGO-COOH were found to be -0.76 eV and - 0.91 eV, respectively, indicating physisorption predominantly through hydrogen bonding. In contrast, PTX@rGO-SO exhibited a higher adsorption energy of -2.09 eV, suggesting chemisorption facilitated by stronger covalent interactions. The presence of these functional groups also enhanced the binding affinity and stability of the drug-nanocarrier complex. Charge transfer analysis revealed that the rGO-COOH and rGO-SO systems exhibited significant changes in electronic properties, with charge transfers estimated at -0.16e and - 0.08e, respectively. These results indicate enhanced electronic coupling between PTX and the functionalized rGO surfaces, which can improve drug loading efficiency and release kinetics. The study also highlights the importance of optimizing surface chemistry to maximize drug interactions, leading to improved therapeutic outcomes. In conclusion, the investigation underscores the potential of functionalized graphene oxide as a promising platform for drug delivery systems. The findings, including the adsorption energies and charge transfer data, provide valuable insights into the interactions between PTX and functionalized rGO, paving the way for the design of optimized nanocarriers capable of enhancing the efficacy of anticancer therapies. The continued exploration of these systems is essential for advancing the field of nanomedicine and improving treatment strategies for cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.